

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 421(TM) anti-human CD3

RRID:AB_2565675

Type: Antibody

Proper Citation

BioLegend Cat# 344834, RRID:AB_2565675

Antibody Information

URL: http://antibodyregistry.org/AB_2565675

Proper Citation: BioLegend Cat# 344834, RRID:AB_2565675

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone SK7

Antibody ID: AB_2565675

Vendor: BioLegend

Catalog Number: 344834

Alternative Catalog Numbers: 344833

Record Creation Time: 20250820T043626+0000

Record Last Update: 20250820T192600+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Decker AH, et al. (2025) Interleukin-6 in synovial fluid drives the conversion of DC2s to DC3s in inflammatory arthritis. iScience, 28(7), 112957.

Seo S, et al. (2025) Allelic bias contributes to heterogeneous phenotypes of NK cell deficiency. Cell reports, 44(8), 116102.

Navin I, et al. (2025) TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer immunology research, 13(10), 1576.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Reinstein ZZ, et al. (2024) Preexisting Skin-Resident CD8 and ?? T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy. Cancer discovery, 14(9), 1631.

Yao Y, et al. (2022) Mucus sialylation determines intestinal host-commensal homeostasis. Cell, 185(7), 1172.

Mudd PA, et al. (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 185(4), 603.

Kosti P, et al. (2021) Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell reports. Medicine, 2(4), 100227.

Kosti P, et al. (2021) Generation of hypoxia-sensing chimeric antigen receptor T cells. STAR protocols, 2(3), 100723.